PRINCETON, N.J., November 7th, 2017 (via PR NEWSWIRE) – Akriveia Therapeutics Inc., an immuno-oncology focused biotechnology company, today announced its Aklusion™ platform for tumor-targeting cancer immunotherapies will be featured in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting, November 10-12, 2017, at Gaylord National Hotel & Convention Center in National Harbor, MD.
Thousand Oaks, CA, November 10, 2016 – Akriveia Therapeutics, an emerging immuno-oncology focused biotechnology company, today announced recent key additions to its research leadership team. Dr. C. Glenn Begley has joined the company as Chief Scientific Officer and Dr. Margaret Karow has joined as Vice President of Discovery and Preclinical Development.
Thousand Oaks, CA, October 12, 2016 – Akriveia Therapeutics LLC, an emerging immuno-oncology focused biotechnology company, today announced its recent $7.5 million Series A investment by F-Prime Capital Partners. Thomas Beck and Ben Auspitz of F-Prime Capital Partners will join Akriveia’s Board of Directors alongside Akriveia’s Chief Executive Officer, Simon Tomlinson, with Dr. Beck becoming Chairman of the Board.